EUVIMEDEUVIMED entdecken
Crossref

Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR signaling pathway

Safaa E Seif, Zeinab Mahmoud iD, Wagnat W Wardakhan, Amr M Abdou, Rasha A Hassan iD

Drug Development Research · 2023

DOI: 10.1002/ddr.22058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Safaa E Seif und 4 weiteren Autor:innen. Beteiligte Einrichtung: Egyptian Drug Authority, Cairo, Egypt. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Antineoplastic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New thieno[2,3‐ d ]pyrimidine derivatives were designed and synthesized. The National Cancer Institute (NCI) evaluated the synthesized novel compounds against a panel of 60 tumor cell lines for their antiproliferative activity. Compounds 6b , 6f , and 6g showed potent anticancer activity at 10 µM dose, with mean GI of 20.86%, 76.41%, and 31.49%, respectively. Compound 6f was selected for five‐dose concentrations evaluation. Compound 6f scored a submicromolar range of GI 50 values against 10 cancer cell lines, indicating broad‐spectrum and potent antiproliferative activity. Compound 6f TGI values were recorded in the cytostatic range of 4.02–95.1 µM. In comparison to sorafenib, the tested compounds 6b , 6f , and 6g inhibited VEGFR‐2 with IC 50 values of 0.290 ± 0.032, 0.066 ± 0.004, and 0.16 ± 0.006 µM, correspondingly. Compound 6f significantly reduced the total VEGFR‐2 expression and its phosphorylation. Additionally, 6f reduced the phosphorylation of PI3K, Akt, and mTOR pathway proteins. Moreover, the migratory potential of HUVECs was significantly reduced, after 72 h of treatment with compound 6f , resulting in disrupted wound healing patterns which verified the angiogenesis suppression properties of compound 6f . Compound 6f increased the total apoptosis percentage by 21.27‐fold compared to sorafenib, which caused a 24.11‐fold increase in the total apoptosis percentage. This apoptotic activity was accompanied by a 7.81‐fold increase in the level of apoptotic caspase‐3. Furthermore, the cell cycle analysis revealed that the target derivative 6f reduced cellular proliferation and induced an arrest in HCT‐15 colon cancer cell cycle at the S phase. Molecular modeling was used to determine the binding profile and affinity of derivative 6f toward the VEGFR‐2 active site.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktAntineoplastic AgentsMolecular StructureStructure-Activity RelationshipPhosphatidylinositol 3-KinasesDown-RegulationSorafenibVascular Endothelial Growth Factor Receptor-2Signal TransductionCell ProliferationTOR Serine-Threonine KinasesPyrimidinesDrug Screening Assays, AntitumorDrug DesignProtein Kinase InhibitorsMolecular Docking Simulation

Stichwörter der Autor:innen

VEGFR-2 inhibitioncytotoxic activitythienopyrimidine

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesSorafenibVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsTOR Serine-Threonine KinasesPyrimidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Egyptian Drug Authority, Cairo, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Department of Microbiology and Immunology, National Research Centre, Giza, Egypt.

ORCID-Profile: Zeinab Mahmoud, Rasha A Hassan

Zitieren

APA

Seif, S. E., Mahmoud, Z., Wardakhan, W. W., Abdou, A. M., & Hassan, R. A. (2023). Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR signaling pathway. Drug Development Research. https://doi.org/10.1002/ddr.22058

Vancouver

Seif SE, Mahmoud Z, Wardakhan WW, Abdou AM, Hassan RA. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR signaling pathway. Drug Development Research. 2023. doi:10.1002/ddr.22058

BibTeX
@article{Seif2023,
  author = {Seif, Safaa E and Mahmoud, Zeinab and Wardakhan, Wagnat W and Abdou, Amr M and Hassan, Rasha A},
  title = {Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR signaling pathway},
  journal = {Drug Development Research},
  year = {2023},
  doi = {10.1002/ddr.22058}
}
Kostenlos starten →